CDK9 and prostate carcinoma: Therefore, the use of CDK7 and CDK9 inhibitors in combination with immune checkpoint inhibitors may represent a powerful therapeutic combination, particularly for tumours displaying a “cold” immune microenvironment, as is the case of prostate cancer.